Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Borer
Jeffrey
J
Armstrong
Paul
P
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000293:Adolescent; D000328:Adult; D026683:Advisory Committees; D000890:Anti-Infective Agents / Q000009:adverse effects; D001372:Aza Compounds; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004562:Electrocardiography / Q000187:drug effects; D024841:Fluoroquinolones; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D018783:Impotence, Vasculogenic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines; D018570:Risk Assessment; D013450:Sulfones; D014227:Triazines; D014481:United States; D014486:United States Food and Drug Administration; D000069058:Vardenafil Dihydrochloride
D000890:Anti-Infective Agents; D001372:Aza Compounds; D002317:Cardiovascular Agents; D024841:Fluoroquinolones; D007093:Imidazoles; D010879:Piperazines; D011799:Quinazolines; D011804:Quinolines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; C047638:alfuzosin; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human; D000077266:Moxifloxacin